nach oben

Current Hematologic Malignancy Reports

Erschienen in:

26.05.2022 | ACUTE LYMPHOCYTIC LEUKEMIA (R. MESA, SECTION EDITOR)

MRD in ALL: Optimization and Innovations

verfasst von: Eric Pierce, Benjamin Mautner, Joseph Mort, Anastassia Blewett, Amy Morris, Michael Keng, Firas El Chaer

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Measurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL). Identifying patients with MRD has the potential to decrease the risk of relapse with the initiation of early salvage therapy and to help guide decision making regarding allogeneic hematopoietic cell transplantation. In this review, we discuss MRD in ALL, focusing on advantages and limitations between MRD testing techniques and how to monitor MRD in specific patient populations.

Recent Findings

MRD has traditionally been measured through bone marrow samples, but more data for evaluation of MRD via peripheral blood is emerging. Current and developmental testing strategies for MRD include multiparametric flow cytometry (MFC), next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and ClonoSeq. Novel therapies are incorporating MRD as an outcome measure to demonstrate efficacy, including blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor T (CAR-T) cell therapy.

Summary

Understanding how to incorporate MRD testing into the management of ALL could improve patient outcomes and predict efficacy of new therapy options.

Bassan R. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–62. https://doi.org/10.1182/blood-2008-11-185132.CrossRefPubMed

Brüggemann M. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–23. https://doi.org/10.1182/blood-2005-07-2708.CrossRefPubMed

Mortuza FY. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(4):1094–104. https://doi.org/10.1200/JCO.2002.20.4.1094.CrossRefPubMed

Holowiecki J. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008;142(2):227–37. https://doi.org/10.1111/j.1365-2141.2008.07185.x.CrossRefPubMed

Patel B. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148(1):80–9. https://doi.org/10.1111/j.1365-2141.2009.07941.x.CrossRefPubMed

• Berry DA. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. https://doi.org/10.1001/jamaoncol.2017.0580. This meta-analysis including 39 studies showed significantly improved event-free survival and overall survival for adult and pediatric patients with ALL who achieved MRD negativity following induction therapy.CrossRefPubMedPubMedCentral

Cassaday RD. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. Am J Hematol. 2018;93(4):546–52. https://doi.org/10.1002/ajh.25030.CrossRefPubMed

Ravandi F. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–21. https://doi.org/10.1182/blood-2012-11-466482.CrossRefPubMedPubMedCentral

Stock W. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–59. https://doi.org/10.1182/blood-2018-10-881961.CrossRefPubMedPubMedCentral

10.

Samra B. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70. https://doi.org/10.1186/s13045-020-00905-2.CrossRefPubMedPubMedCentral

11.

Blinatumomab [package insert]. Thousand Oaks, CA: Amgen Inc.; 2022. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf. Accessed 24 May 2022.

12.

Cavé H. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339(9):591–8. https://doi.org/10.1056/NEJM199808273390904.CrossRefPubMed

13.

Foroni L. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol. 1999;105(1):7–24.PubMed

14.

van Dongen JJJM. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731–8. https://doi.org/10.1016/S0140-6736(98)04058-6.CrossRefPubMed

15.

Brisco J. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 1996;87(12):5251–6.CrossRef

16.

Foroni L. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia. 1997;11(10):1732–41. https://doi.org/10.1038/sj.leu.2400841.CrossRefPubMed

17.

Krampera M. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol. 2003;120(1):74–9. https://doi.org/10.1046/j.1365-2141.2003.03974.x.CrossRefPubMed

18.

Ravandi F. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016;172(3):392–400. https://doi.org/10.1111/bjh.13834.CrossRefPubMed

19.

Vidriales MB. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101(12):4695–700. https://doi.org/10.1182/blood-2002-08-2613.CrossRefPubMed

20.

Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Grardel N, Chalandon Y, Boissel N. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739–49. https://doi.org/10.1182/blood-2014-01-547695.CrossRefPubMed

21.

Gökbuget N. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–76. https://doi.org/10.1182/blood-2011-09-377713.CrossRefPubMed

22.

Gökbuget N. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24(1):337–48. https://doi.org/10.1080/16078454.2019.1567654.CrossRefPubMed

23.

Nagafuji K. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013;6:14. https://doi.org/10.1186/1756-8722-6-14.CrossRefPubMedPubMedCentral

24.

Ribera JM. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–604. https://doi.org/10.1200/JCO.2013.52.2425.CrossRefPubMed

25.

Salah-Eldin. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study. Med Oncol. 2014;31(5):938. https://doi.org/10.1007/s12032-014-0938-z.CrossRefPubMed

26.

Raff T. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910–5. https://doi.org/10.1182/blood-2006-07-037093.CrossRefPubMed

27.

Brown PA. Acute lymphoblastic leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19(9):1079–109. https://doi.org/10.6004/jnccn.2021.0042.CrossRef

28.

Ribera JM. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879–94. https://doi.org/10.1182/blood.2020007311.CrossRefPubMed

29.

Götz G. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992;64(2):97–100. https://doi.org/10.1007/BF01715353.CrossRefPubMed

30.

Liu-Dumlao T. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14(5):387–94. https://doi.org/10.1007/s11912-012-0247-7.CrossRefPubMedPubMedCentral

31.

Dombret H. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357–66. https://doi.org/10.1182/blood-2002-03-0704.CrossRefPubMed

32.

Pane F. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia. 2005;19(4):628–35. https://doi.org/10.1038/sj.leu.2403683.CrossRefPubMed

33.

Kim DY. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–56. https://doi.org/10.1182/blood-2015-03-636548.CrossRefPubMed

34.

Chiaretti S. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101(12):1544–52. https://doi.org/10.3324/haematol.2016.144535.CrossRefPubMedPubMedCentral

35.

Foà R. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–8. https://doi.org/10.1182/blood-2011-05-351403.CrossRefPubMed

36.

Ottmann OG. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007;109(10):2068–76. https://doi.org/10.1002/cncr.22631.CrossRefPubMed

37.

Rousselot P. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774–82. https://doi.org/10.1182/blood-2016-02-700153.CrossRefPubMedPubMedCentral

38.

Bassan R. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e225. https://doi.org/10.1038/bcj.2014.48.CrossRefPubMedPubMedCentral

39.

Spinelli O. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612–8. https://doi.org/10.3324/haematol.10965.CrossRefPubMed

40.

• Shen Z. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755. https://doi.org/10.1186/s12885-018-4670-5. This meta-analysis including 21 studies showed patients with positive MRD prior to allogeneic stem cell transplantation was a significant negative predictor of relapse-free survival, event-free survival, and overall survival as compared to those with negative MRD.CrossRefPubMedPubMedCentral

41.

Akahoshi Y. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2021;113(6):832–9. https://doi.org/10.1007/s12185-021-03094-x.CrossRefPubMed

42.

• Li S. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL. Front Oncol. 2020;10:320. https://doi.org/10.3389/fonc.2020.00320. This retrospective study evaluated the effects of MRD positivity prior to allogeneic HCT for management of Philadelphia chromosome positive ALL and revealed that haploidentical HCT was related to higher probability of survival and lower incidences of relapse as compared to matched sibling donor HCT in this patient population.CrossRefPubMedPubMedCentral

43.

Lee S. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2009;115(3):561–70. https://doi.org/10.1002/cncr.24026.CrossRefPubMed

44.

Lee S. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26(11):2367–74. https://doi.org/10.1038/leu.2012.164.CrossRefPubMed

45.

Lou Y. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Med. 2017;11(2):229–38. https://doi.org/10.1007/s11684-017-0506-y.CrossRefPubMed

46.

Lussana F. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22(11):1983–7. https://doi.org/10.1016/j.bbmt.2016.07.021.CrossRefPubMed

47.

Mizuta S. Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J. 2012;2(5):e72. https://doi.org/10.1038/bcj.2012.18.CrossRefPubMedPubMedCentral

48.

Nishiwaki S. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51(1):43–50. https://doi.org/10.1038/bmt.2015.217.CrossRefPubMed

49.

Akahoshi Y. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant. 2020;55(7):1317–25. https://doi.org/10.1038/s41409-020-0951-0.CrossRefPubMed

50.

Bachanova V. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658–65. https://doi.org/10.1038/leu.2013.253.CrossRefPubMed

51.

Terwey T. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20(10):1522–9. https://doi.org/10.1016/j.bbmt.2014.05.026.CrossRefPubMed

52.

Zhao X. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012;91(2):183–92. https://doi.org/10.1007/s00277-011-1285-1.CrossRefPubMed

53.

Zhou Y. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14(4):319–26. https://doi.org/10.1016/j.clml.2014.01.002.CrossRefPubMedPubMedCentral

54.

Miyamura K. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood. 1992;79(5):1366–70.CrossRef

55.

Radich J. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89(7):2602–9.CrossRef

56.

Stirewalt DL. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9(3):206–12. https://doi.org/10.1053/bbmt.2003.50025.CrossRefPubMed

57.

Zhao X. Comparative analysis of flow cytometry and RQ-PCR for the detection of minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(9):1936–43. https://doi.org/10.1016/j.bbmt.2018.03.015.CrossRefPubMed

58.

Candoni A. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant. 2019;25(12):2388–97. https://doi.org/10.1016/j.bbmt.2019.07.037.CrossRefPubMed

59.

Chen H. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol. 2012;5:29. https://doi.org/10.1186/1756-8722-5-29.CrossRefPubMedPubMedCentral

60.

Pfeifer H. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254–62. https://doi.org/10.1038/leu.2012.352.CrossRefPubMed

61.

Löffler A. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–103.CrossRef

62.

Kantarjian H. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. https://doi.org/10.1056/NEJMoa1609783.CrossRefPubMedPubMedCentral

63.

Martinelli G. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–802. https://doi.org/10.1200/JCO.2016.69.3531.CrossRefPubMed

64.

Topp MS. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–8. https://doi.org/10.1200/JCO.2010.32.7270.CrossRefPubMed

65.

Topp MS. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–7. https://doi.org/10.1182/blood-2012-07-441030.CrossRefPubMed

66.

Zugmaier G. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–84. https://doi.org/10.1182/blood-2015-06-649111.CrossRefPubMedPubMedCentral

67.

• Gökbuget N. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31. https://doi.org/10.1182/blood-2017-08-798322. This prospective, single-arm, phase II study showed that a majority of patients in hematologic remission with MRD positivity after chemotherapy achieved a complete MRD response to blinatumomab and a significant OS improvement in MRD responders.CrossRefPubMedPubMedCentral

68.

DiJoseph JF. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14. https://doi.org/10.1182/blood-2003-07-2466.CrossRefPubMed

69.

Kantarjian HM. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53. https://doi.org/10.1056/NEJMoa1509277.CrossRefPubMedPubMedCentral

70.

Stock W. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127(6):905–13. https://doi.org/10.1002/cncr.33321.CrossRefPubMed

71.

Park JH. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. https://doi.org/10.1056/NEJMoa1709919.CrossRefPubMedPubMedCentral

72.

Shah BD. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. https://doi.org/10.1016/S0140-6736(21)01222-8.CrossRefPubMed

73.

van der Velden VH. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604–11. https://doi.org/10.1038/sj.leu.2404586.CrossRefPubMed

74.

Riva G. Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges. Cancers (Basel). 2021;13(18):4582. https://doi.org/10.3390/cancers13184582.CrossRef

75.

DiGiuseppe JA. Applications of flow cytometric immunophenotyping in the diagnosis and posttreatment monitoring of B and T lymphoblastic leukemia/lymphoma. Cytometry B Clin Cytom. 2019;96(4):256–65. https://doi.org/10.1002/cyto.b.21833.CrossRefPubMed

76.

Theunissen P. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129(3):347–57. https://doi.org/10.1182/blood-2016-07-726307.CrossRefPubMedPubMedCentral

77.

Al-Mawali A. The role of multiparameter flow cytometry for detection of minimal residual disease in acute Myeloid Leukemia. Am J Clin Pathol. 2009;131(1):16–26. https://doi.org/10.1309/AJCP5TSD3DZXFLCX.CrossRefPubMed

78.

Brüggemann M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120(23):4470–81. https://doi.org/10.1182/blood-2012-06-379040.CrossRefPubMed

79.

Modvig S. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. Leukemia. 2021;35(7):1894–906. https://doi.org/10.1038/s41375-020-01100-5.CrossRefPubMed

80.

Alekseyev YO. A next-generation sequencing primer—how does it work and what can it do? Acad Pathol. 2018;5:2374289518766521. https://doi.org/10.1177/2374289518766521.CrossRefPubMedPubMedCentral

81.

Kruse A. Minimal residual disease detection in acute lymphoblastic leukemia. Int J Mol Sci. 2020;21(3):1054. https://doi.org/10.3390/ijms21031054.CrossRefPubMedCentral

82.

Faham M. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173–80. https://doi.org/10.1182/blood-2012-07-444042.CrossRefPubMedPubMedCentral

83.

Panuzzo C. Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling. J Clin Med. 2022;11(3):483. https://doi.org/10.3390/jcm11030483.CrossRefPubMedPubMedCentral

84.

Sala Torra O. Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2017;23(4):691–6. https://doi.org/10.1016/j.bbmt.2016.12.639.CrossRefPubMed

85.

Pulsipher MA. IgH-V(D) J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015;125(22):3501–8. https://doi.org/10.1182/blood-2014-12-615757.CrossRefPubMedPubMedCentral

86.

Kotrova M. Is next-generation sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia? Mol Diagn Ther. 2017;21(5):481–92. https://doi.org/10.1007/s40291-017-0277-9.CrossRefPubMed

87.

Zhang J. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing. Brief Bioinform. 2014;15(2):244–55. https://doi.org/10.1093/bib/bbt042.CrossRefPubMed

88.

Brüggemann M. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 2019;33(9):2241–53. https://doi.org/10.1038/s41375-019-0496-7.CrossRefPubMedPubMedCentral

89.

Rellick SL. Co-culture model of B-cell acute lymphoblastic leukemia recapitulates a transcription signature of chemotherapy-refractory minimal residual disease. Sci Rep. 2021;11(1):15840. https://doi.org/10.1038/s41598-021-95039-x.CrossRefPubMedPubMedCentral

90.

Hong Y. Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib. BMC Cancer. 2021;21(1):1331. https://doi.org/10.1186/s12885-021-09076-w.CrossRefPubMedPubMedCentral

91.

Merli P. Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant? Front Pediatr. 2021;9:777108. https://doi.org/10.3389/fped.2021.777108.CrossRefPubMedPubMedCentral

92.

Tüfekçi Ö. Assessment of minimal residual disease in childhood acute lymphoblastic leukemia: a multicenter study from Turkey. J Pediatr Hematol Oncol. 2022;44(2):e396–402. https://doi.org/10.1097/MPH.0000000000002419.CrossRefPubMed

93.

Huang YJ. Comparison of two quantitative PCR-based assays for detection of minimal residual disease in B-precursor acute lymphoblastic leukemia harboring three major fusion transcripts. J Mol Diagn. 2021;23(10):1373–9. https://doi.org/10.1016/j.jmoldx.2021.07.008.CrossRefPubMed

94.

Flohr T. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–82. https://doi.org/10.1038/leu.2008.5.CrossRefPubMed

95.

van der Velden VH. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol. 2009;538:115–50. https://doi.org/10.1007/978-1-59745-418-6_7.CrossRefPubMed

96.

Germano G. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia. 2003;17(8):1573–82. https://doi.org/10.1038/sj.leu.2403008.CrossRefPubMed

97.

Monter A. ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev Mol Diagn. 2019;19(7):571–8. https://doi.org/10.1080/14737159.2019.1627877.CrossRefPubMed

98.

Walzer S. A cost impact analysis of clonoSEQ. Oncol Ther. 2021;9(2):607–19. https://doi.org/10.1007/s40487-021-00169-x.CrossRefPubMedPubMedCentral

99.

Hussaini MO. Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies. Arch Pathol Lab Med. 2022;146(4):485–93. https://doi.org/10.5858/arpa.2020-0457-OA.CrossRefPubMed

100.

• Kotrova M. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia. 2020;34(4):1154–7. https://doi.org/10.1038/s41375-019-0599-1. This retrospective study evaluated bone marrow and peripheral blood sample pairs from B-ALL and T-ALL patients using EuroMRD allele-specific oligonucleotide RQ-PCR and EuroMRD guidelines and revealed stronger correlation of MRD in bone marrow and peripheral blood in T-cell ALL when compared to B-cell ALL.CrossRefPubMed

101.

Brisco MJ. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol. 1997;99(2):314–9. https://doi.org/10.1046/j.1365-2141.1997.3723186.x.CrossRefPubMed

102.

van der Velden VH. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002;16(8):1432–6. https://doi.org/10.1038/sj.leu.2402636.CrossRefPubMed

103.

Muffly L. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 2021;5(16):3147–51. https://doi.org/10.1182/bloodadvances.2021004234.CrossRefPubMedPubMedCentral

104.

Keegan A. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018;71(7):653–8. https://doi.org/10.1136/jclinpath-2017-204828.CrossRefPubMed

105.

Pemmaraju N. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017;92(3):279–85. https://doi.org/10.1002/ajh.24629.CrossRefPubMedPubMedCentral

106.

Spyridonidis A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood. 2020;135(19):1639–49. https://doi.org/10.1182/blood.2019003566.CrossRefPubMed

Titel: MRD in ALL: Optimization and Innovations
verfasst von: Eric Pierce
Benjamin Mautner
Joseph Mort
Anastassia Blewett
Amy Morris
Michael Keng
Firas El Chaer
Publikationsdatum: 26.05.2022
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 4/2022
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-022-00664-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

MRD in ALL: Optimization and Innovations

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie